Elevance Health Inc. closed 26.44% below its 52-week high of $567.26, which the company reached on September 3rd.

Elevance Health (NYSE:ELV – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday. A number ...

Regulatory changes under Trump's administration and AI integration are key factors influencing Elevance Health's future ...

We recently compiled a list of the Top 10 Health Insurance Stocks To Buy. In this article, we are going to take a look at ...

Elevance Health (NYSE:ELV) traded higher in the premarket on Tuesday, a move attributed to comments made by the company's CFO ...

Daneshvar Rohinton of iA Global Asset Management is expecting an economic realignment as many countries look at becoming more ...

Shares of Elevance Health, Inc. (NYSE:ELV – Get Free Report) have been assigned an average rating of “Moderate Buy” from the ...

In a regulatory filing, Elevance Health (ELV) disclosed that its officers will speak with investors over the next several weeks. During these ...

Shares of Elevance Health Inc. ELV shed 2.61% to $411.04 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.49% to 5,599.30 ...

Health insurers, including Cigna, Humana and Elevance Health, are tucking changes to DEI strategies and business risks into ...

Artisan Partners, an investment management company, released its “Artisan Select Equity Fund” fourth quarter 2024 investor ...

Many stock analysts see Indianapolis-based Elevance’s recent struggles as an opportunity. Thirteen of 24 analysts tracked by The Wall Street Journal rate the health insurer as a buy.